Product Information:

TIRZEE 2.5mg Pen contains Tirzepatide 2.5mg, a once-weekly dual GIP and GLP-1 receptor agonist used for the treatment of type 2 diabetes mellitus and chronic weight management in adults. Tirzepatide mimics the actions of two incretin hormones—glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)—to enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety.

The 2.5mg dose is the starting dose in the titration regimen and is not intended for long-term maintenance.

✅ Note: This aligns with globally approved products like Mounjaro® (for diabetes) and Zepbound® (for obesity), where 2.5mg is the initial weekly dose.

Uses of (TIRZEE 2.5MG PEN):

1. Type 2 diabetes mellitus – as part of stepwise dose escalation
2. Chronic weight management – as the initiation dose in obesity treatment (off-label at this stage; full effect requires higher doses)

Key Benefits of (TIRZEE 2.5MG PEN):

1. Once-weekly subcutaneous injection – improves adherence
2. Dual hormone action provides superior glycemic and weight control vs. GLP-1 agonists alone
3. Significant HbA1c reduction (up to 2.0–2.5% at higher doses)
4. Promotes early satiety and reduced caloric intake
5. Low risk of hypoglycemia when not combined with insulin or sulfonylureas

How To Use (TIRZEE 2.5MG PEN):

1. Inject once weekly, on the same day each week, with or without meals.
2. Administer subcutaneously in the abdomen, thigh, or upper arm.
3. Do not inject intravenously or intramuscularly.
4. Dose escalation is mandatory:
5. Weeks 1–4: 2.5mg once weekly
6. Weeks 5–8: Increase to 5mg once weekly
7. Further escalate to 7.5mg, 10mg, 12.5mg, or 15mg based on response and tolerability
8. If a dose is missed, administer within 4 days; if >4 days, skip and resume on the next scheduled day.

When Not to Use (TIRZEE 2.5MG PEN):

Do not use if you have:

1. Personal or family history of medullary thyroid carcinoma (MTC)
2. Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
3. Hypersensitivity to tirzepatide or any excipients
4. Type 1 diabetes or diabetic ketoacidosis

⚠️ Black Box Warning:

Tirzepatide causes thyroid C-cell tumors in rodents. It is contraindicated in patients with MTC risk.

Side Effects of (TIRZEE 2.5MG PEN):

Common (usually mild at 2.5mg, but may increase with dose):

1. Nausea, vomiting, diarrhea, constipation
2. Decreased appetite, abdominal discomfort
3. Injection site reactions (redness, itching)

Less common:

1. Fatigue, dizziness
2. Elevated amylase/lipase levels

Serious (rare but require monitoring):

1. Acute pancreatitis (persistent severe abdominal pain)—discontinue immediately
2. Gallbladder disorders (gallstones, cholecystitis)
3. Acute kidney injury (from dehydration due to GI losses)
4. Diabetic retinopathy complications (in patients with pre-existing disease)
5. Seek medical help if severe abdominal pain, vision changes, or persistent vomiting occurs.

Dosage: (TIRZEE 2.5MG PEN):

1. Starting dose: 2.5mg once weekly for 4 weeks
2. Not a maintenance dose—must escalate to achieve therapeutic effect
3. Maximum dose: 15mg once weekly

Who It’s For (TIRZEE 2.5MG PEN):

Adults with type 2 diabetes or obesity beginning tirzepatide therapy and requiring gradual dose titration to improve gastrointestinal tolerability.

Warnings & Precautions:

1. Ensure adequate hydration to prevent renal injury
2. Monitor for signs of pancreatitis or gallbladder disease
3. Use caution in patients with diabetic retinopathy
4. Educate on proper injection technique and pen handling

Drug Interactions:

1. Insulin or sulfonylureas: ↑ Risk of hypoglycemia
2. Oral medications: May delay absorption due to slowed gastric emptying
3. Always inform your doctor about all medications.

Additional Information:

1. Store unused pens refrigerated (2–8°C); after first use, store at room temperature (<30°C) for up to 28 days.
2. Do not freeze. Protect from light.
3. Keep out of reach of children. Available by prescription in Pakistan.